FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marc...
2 Apr 202447min
ELCC 2024 Highlights
This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Prague. Host Dr. Stephen Liu discusses the important research presented at the meeting with D...
28 Mar 202458min
Emerging Agents In Small Cell Lung Cancer
Small cell lung cancer is a challenging subtype of lung cancer to treat because most patients present with extensive-stage disease. Unlike non-small cell lung cancer, treatments are more limited. Fo...
19 Mar 202441min
Radiopharmaceuticals and Lung Cancer
This episode of Lung Cancer Considered focuses on radiopharmaceuticals-- a unique class of drugs that may have the most immediate impact in neuroendocrine tumors. Host Dr. Stephen Liu leads a discuss...
5 Mar 202454min
FDA Approval: 1L Amivantamab plus Chemotherapy for EGFR Exon 20 NSCLC
Amivantamab Approved by FDA today, March 1! In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of first-line amivantamab plus chemotherapy for NSCL...
1 Mar 202428min
Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC
Today’s episode of Lung Cancer Considered is part of our special series on seminal trials in thoracic oncology, focusing on the phase I study of the PD-1 inhibitor nivolumab. Hosts Dr. Narjust Florez ...
29 Feb 202432min
From the Basics to Next Line Therapy: ALK + NSCLC
ALK fusions represent 3-5% of newly diagnosed non-small cell lung cancers but several therapeutic options do exist. Lung Cancer Considered host Dr. Narjust Florez and guests Dr. Christine Lovly from ...
27 Feb 202446min
Best Practice for RET NSCLC
Lung Cancer Considered Host Dr. Stephen Liu moderates a discussion in this podcast on RET as a therapeutic target. RET fusions are a known actionable alteration and this field has blossomed very quick...
20 Feb 202434min
